Financial Report: BMS

BMS

3Q Revenues: $3.9 billion (-4%)

3Q Earnings: $721 million (+4%)

YTD Revenues: $11.6 billion (-3%)

YTD Earnings: $2.0 billion (+8%)

Comments: Excluding the divested Diabetes Alliance, global revenues increased 7%. Baraclude sales were down 14% to $325 million. Reyataz sales were down 10% to $338 million. Sustiva Franchise sales were $357 million, down 8% and Abilify sales were down 21% to $449 million. Eliquis sales grew by $175 million. Yervoy sales were up 47% to $350 million. Sprycel sales were up 22% to $385 million. Orencia sales grew 18% to $444 million. U.S. revenues decreased 3% to $2.0 billion in the quarter. International revenues decreased 4%. R&D expenses increased 10% to $983 million in the quarter.